Investigational Darunavir-Based Single-Tablet Regimen Shows Positive Results in Previously Untreated HIV Patients in Pivotal Phase 3 AMBER Clinical Trial

AMBER 48-week safety and efficacy results to be presented at the 16th European AIDS Conference
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news